| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 7.1% stake in Aligos Therapeutics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| BLATT LAWRENCE reports a 6.5% stake in Aligos Therapeutics, Inc. |
| 12/27/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 11/02/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/04/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/04/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/29/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/22/2022 |
8-K
| Other Events Interactive Data |
| 03/10/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/10/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/10/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G
| EcoR1 Capital, LLC reports a 7.5% stake in Aligos Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| Logos Global Management LP reports a 0% stake in Aligos Therapeutics, Inc. |
| 02/14/2022 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 5.3% stake in Aligos Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 5.6% stake in Aligos Therapeutics, Inc. |
| 02/14/2022 |
SC 13G
| JANUS HENDERSON GROUP PLC reports a 5.7% stake in Aligos Therapeutics, Inc. |
|